WBO:VRTX (USA)
Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
50 Northern Avenue, Boston, MA, USA, 02210
Compare
Compare
Traded in other countries / regions
VRTX.Austria
•
VRTX34.Brazil
•
VX1.Germany
•
VRTX.Mexico
•
VRTX.Switzerland
•
0QZU.UK
•
VRTX.USA
Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.92 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.21 | |||||
| Interest Coverage | 68.24 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 14.92 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 35.3 | |||||
| 3-Year EBITDA Growth Rate | 57.5 | |||||
| 3-Year EPS without NRI Growth Rate | 3.7 | |||||
| 3-Year FCF Growth Rate | 26.9 | |||||
| 3-Year Book Growth Rate | 31.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 47.51 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 10.27 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.29 | |||||
| 9-Day RSI | 59 | |||||
| 14-Day RSI | 57.84 | |||||
| 6-1 Month Momentum % | 39.11 | |||||
| 12-1 Month Momentum % | 73.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | |||||
| Quick Ratio | 4.36 | |||||
| Cash Ratio | 3.62 | |||||
| Days Inventory | 126.25 | |||||
| Days Sales Outstanding | 50.63 | |||||
| Days Payable | 60.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.1 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.13 | |||||
| Operating Margin % | 48.91 | |||||
| Net Margin % | 38.26 | |||||
| ROE % | 30.92 | |||||
| ROA % | 23.45 | |||||
| ROIC % | 80.53 | |||||
| ROC (Joel Greenblatt) % | 286.34 | |||||
| ROCE % | 34.73 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.81 | |||||
| Forward PE Ratio | 20.88 | |||||
| PE Ratio without NRI | 23.81 | |||||
| Shiller PE Ratio | 90.35 | |||||
| Price-to-Owner-Earnings | 22.76 | |||||
| PEG Ratio | 0.19 | |||||
| PS Ratio | 9.11 | |||||
| PB Ratio | 6.32 | |||||
| Price-to-Tangible-Book | 7.15 | |||||
| Price-to-Free-Cash-Flow | 20.09 | |||||
| Price-to-Operating-Cash-Flow | 18.93 | |||||
| EV-to-EBIT | 16.81 | |||||
| EV-to-Forward-EBIT | 14.25 | |||||
| EV-to-EBITDA | 16.25 | |||||
| EV-to-Forward-EBITDA | 13.77 | |||||
| EV-to-Revenue | 8.04 | |||||
| EV-to-Forward-Revenue | 7.67 | |||||
| EV-to-FCF | 17.72 | |||||
| Price-to-Projected-FCF | 2.16 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.95 | |||||
| Price-to-Graham-Number | 2.75 | |||||
| Price-to-Net-Current-Asset-Value | 9.6 | |||||
| Price-to-Net-Cash | 13.46 | |||||
| Earnings Yield (Greenblatt) % | 5.95 | |||||
| Forward Rate of Return (Yacktman) % | 22.58 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7,502.891 | ||
| EPS (TTM) (€) | 11.092 | ||
| Beta | 0 | ||
| Volatility % | 26.96 | ||
| 14-Day RSI | 57.84 | ||
| 14-Day ATR (€) | 5.27308 | ||
| 20-Day SMA (€) | 279.72 | ||
| 12-1 Month Momentum % | 73.07 | ||
| 52-Week Range (€) | 151.62 - 293.1 | ||
| Shares Outstanding (Mil) | 256.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||